The serum concentration of soluble interleukin-2 receptor in patients with Kawasaki disease

Abstract

Kawasaki disease is a febrile disease of childhood that is associated with increased inflammatory cytokines and immunoregulatory abnormalities. While the serum concentrations of soluble IL-2 receptor can change under such pathologies, the relevance of the soluble IL-2 receptor concentration in patients with Kawasaki disease has not been specified. We aimed to summarize the existing studies that reported the soluble IL-2 receptor concentrations in patients with Kawasaki disease. Original articles that were published up to July 2016 were collected using a PubMed/Medline-based search engine. A total of nine articles that reported the serum soluble IL-2 receptor concentrations in acute-phase Kawasaki disease were eligible. All of the articles described a high soluble IL-2 receptor concentration in patients with Kawasaki disease relative to the level of controls or the reference range. Two of five articles on patients with coronary artery aneurysms described a significantly higher soluble IL-2 receptor concentration in patients with coronary artery aneurysms than patients without. Two articles on patients with intravenous immunoglobulin therapy described a significant decrease of the soluble IL-2 receptor concentration after the therapy. Accordingly, the serum soluble IL-2 receptor can be a potent marker of disease activity and therapeutic effects in patients with Kawasaki disease; further studies are thus warranted for its use in the clinical setting.

Keywords

Interleukin-2 CD25 coronary aneurysm mucocutaneous lymph node syndrome intravenous immunoglobulin therapy

Introduction

Kawasaki disease (KD) is a febrile disease of childhood, which predominantly occurs in males and is sometimes complicated by coronary lesions.¹ The incidence of KD, which is more commonly seen in Asian countries than in other countries, is increasing.^2,3 Although the causes of KD have not been fully elucidated, organism infection is thought to be a cause of the disease.⁴ With immunoregulatory disorders, inflammatory conditions with the enhancement of cytokine molecules, such as interleukin (IL)-1, IL-6, and tumor necrosis factor (TNF)-α, accompany the disease.^4–6

Of note, IL-2 is one of the inflammatory cytokines. While immunoregulatory disorders, including the activation of T-cells, with the enhancement of cytokines arise in patients with KD,⁷ the activation of T cells leads to appearance of IL-2 receptors on the cell surface, and then its α-chain (CD25), an IL-2 receptor component, is released into circulation by protease.^8,9 A fragment of CD25 is known as soluble IL-2 receptor (sIL-2R).^8,9 Although the measurement of IL-2 itself is difficult due to its short-term behaviour, the concentration of sIL-2R can be measured in blood samples.

Currently, the serum sIL-2R is often used as a marker for diagnosis and treatment of malignant lymphoma in daily practice.⁹ In paediatric patients, the sIL-2R concentration is also included in the diagnostic guidelines for haemophagocytic lymphohistiocytosis.¹⁰ Basically, sIL-2R is a non-specific marker. Can the serum concentration be useful for considering the disease states of patients with KD? The present study aimed to summarize the existing studies that reported on the sIL-2R concentrations of KD patients in order to characterize the utility of sIL-2R as a marker in KD.

Methods

We used a PubMed/Medline-based search engine to perform a search of the relevant literature. The following search formula was used: soluble [All Fields] AND (‘receptors, interleukin-2’ [MeSH Terms] OR ‘receptors’ [All Fields] AND ‘interleukin-2’ [All Fields]) OR ‘interleukin-2 receptors’ [All Fields] OR ‘interleukin 2 receptor’ [All Fields] OR ‘interleukin-2 receptor alpha subunit’ [MeSH Terms]) OR (‘interleukin-2’ [All Fields] AND ‘receptor’ [All Fields] AND ‘alpha’ [All Fields] AND ‘subunit’ [All Fields]) OR ‘interleukin-2 receptor alpha subunit’ [All Fields]) AND (‘mucocutaneous lymph node syndrome’ [MeSH Terms] OR ‘mucocutaneous’ [All Fields] AND ‘lymph’ [All Fields] AND ‘node’ [All Fields] AND ‘syndrome’ [All Fields]) OR ‘mucocutaneous lymph node syndrome’ [All Fields]) OR (‘Kawasaki’ [All Fields] AND ‘disease’ [All Fields]) OR ‘Kawasaki disease’ [All Fields]). Original articles, which were published up to July 2016 and were written in English, were included in our search.

The search yielded a total of 15 articles. After our review of their contents, six articles were omitted because four articles were simply written by an author with the name ‘Kawasaki’ (not related to research on KD) and two articles were omitted because they did not focus on the sIL-2R concentration (e.g. cutaneous findings¹¹ and superantigens in relation to T-cell activation¹²).

Results

The nine articles that reported the serum IL-2R concentrations in patients with KD are summarized in Table 1. Four articles were reported from Japan,^5,7,13,14 two were from China,^15,16 and one each was from Korea,⁶ Canada¹⁷ and United States.¹⁸ The age of the study subjects ranged from 3 months to 11 years, while one article¹⁸ did not describe the age range. There were four articles that included both genders,^6,7,15,16 while the gender difference in sIL-2R concentrations was not investigated. The measurements of serum sIL-2R concentrations were performed using an enzyme linked immunosorbent assay in all studies.^{5–7,13–18}

Table 1.

The serum sIL-2R concentrations in patients with Kawasaki disease.

Ref.	Age, years (mean)	Duration of measurements	Subject number	sIL-2R (unit/mL: mean ± standard deviation)	P
13	0.2–5.1 years	Controls	16	737.2 ± 319.5
	(1.8 Years)	3–16 Days	30	2658.6 ± 2397.4	NA
		15–212 Days	30	982.2 ± 593.0	<0.0025^a
14	0.5–3.6 years	Controls	16	958 ± 409
	(2.3 Years)	2–9 Days	9	2810 ± 1166	<0.0005^b
		14–34 Days	9	1154 ± 627	>0.1^b
5	0.2–5 Years	Controls	16	737 ± 320
	(1.9 years)	2–9 Days	45	2653 ± 2156	<0.001^b
15	0.6–9.25 Years	Controls	18	718 ± 406
	(3 years)	3–9 Days	26	3755 ± 2537	≤0.0005^b
		15–42 Days	24	1314 ± 602	≤0.0005^a
16	No description	Controls	22	654 ± 51
		First week	14	3540 ± 878	<0.002^b
		Second week	45	2587 ± 583	<0.02^b
6	0.3–11 Years	Controls	20	315
	(3 years)	3–9 Days	13	3275	NA
		15–42 Days	13	1841	NA
17	0.6–5 Years	Controls	25	32 ± 10
		First week	48	3243 ± 184	<0.05^b
		Second week	48	3992 ± 102	NA
18	0.3–8 Years	Controls	20	2161.53 ± 696.92 pg/mL
		Before IVIG	32	9253.41 ± 2568.38 pg/mL	<0.05^b
		After IVIG	32	5520 ± 696.92 pg/mL	<0.05^a
7	30.3 Months	Reference range	–	220 – 530
		Before IVIG	12	2854 ± 557	NA
		After IVIG	12	1718 ± 443	<0.01^a

NA: not available, IVIG: intravenous immunoglobulin.

Comparison with acute phase.

Comparison with controls.

Almost of the articles described the serum sIL-2R concentrations in both controls and patients with acute-phase KD, while one article⁷ described the reference range instead of the level of controls. The sIL-2R concentrations of controls ranged from 32 to 958 unit/mL, while those of patients with KD ranged from 2653 to 3755 unit/mL (in one article,¹⁶ the used unit to measure sIL-2R differed from that of other articles). All of the articles showed that the sIL-2R concentrations in patients with KD were high relative to those in controls^5,6,13–18 and the reference range,⁷ while statistical analysis comparing between patients with KD and without was not necessarily carried out in one article.⁶

As shown in Table 2, five articles compared the sIL-2R concentrations between patients with coronary artery aneurysms (CAAs) and those without CAAs. Two of these articles showed that the sIL-2R concentration in patients with CAAs was significantly higher than that in those without CAAs.^15,18 In another two articles,^5,13 although the sIL-2R concentration in patients with CAAs was appeared to be mildly high relative to that in patients without CAAs, no statistical analysis was performed.

Table 2.

The serum sIL-2R concentrations and CCAs.

Ref.	CCA state	Subject number	sIL-2R (unit/mL)	P
13	With CAAs	9	2850 ± 2808.6	NA
	Without CAAs	33	2439.3 ± 2044
5	With CAAs	11	3062 ± 3032	NA
	Without CAAs	34	2492 ± 1815
15	With CAAs	8	3235 ± 1156	0.5
	Without CAAs	18	3985 ± 2955
16	With CAAs	12	5100 ± 1910	0.009^a
	Without CAAs	62	1750 ± 109
17	With CAAs	12	4851 ± 146	<0.05^a
	Without CAAs	48	3992 ± 102

CCAs: coronary artery aneurysms, NA: not available.

Comparison between patients with and without CAAs.

Three articles reported the sIL-2R concentrations in the acute and convalescent phases of KD^13,14,17 and two articles showed that the level was significantly higher in the acute phase.^13,17 Furthermore, two articles (one cross-sectional study⁷ and one interventional study¹⁶) compared the sIL-2R concentrations in patients before and after intravenous immunoglobulin (IVIG) therapy.^7,16 The sIL-2R concentration was found to be significantly decreased after therapy.^7,16 On the other hand, the concentration after IVIG therapy remained significantly higher than that in controls,¹⁶ and the concentration in IVIG-resistant patients (15 of 27 patients) was reported to be significantly higher than that in the patients who responded to IVIG.⁷

Discussion

The serum sIL-2R concentration was found to be 3–100 times higher in patients with KD than in controls. While it was only suggested that the sIL-2R concentration in patients with CAAs might be high relative to patients without CAAs, the sIL-2R concentration could be reduced after IVIG therapy. Although the sIL-2R concentrations in patients with KD remain to be characterized, the serum sIL-2R concentration may be a potent marker of disease activity and therapeutic effects in these patients.

By activating T cells, CD25 (α-chain) is overexpressed in the IL-2 receptors and is released into circulation as sIL-2R.^8,9 Blood T cells are activated in acute-phase KD^7,12; thus, the serum sIL-2R concentration can be increased. In addition, the activation of T-cells in KD is assumed to be related to coronary artery damage.^7,12 As this review did not consistently demonstrate that a high sIL-2R concentration might predict CAAs in patients with KD, the predictive value of sIL-2R on CCA formation should be explored in future studies.

Currently, IVIG therapy is used to treat patients with KD.⁴ The IVIG therapy inhibits both the activation of nuclear factor kappa B (NF-κB) and the release of cytokine molecules, including IL-2 (which are induced by CD14⁺ monocytes/macrophages and CD3⁺ T cells), in patients with KD.¹⁹ Thus, the therapeutic mechanism may partly explain the decrease of the sIL-2R concentration that is observed in patients who were treated with IVIG in our review.^7,16 On the other hand, a still-high sIL-2R concentration was observed after therapy and/or in IVIG-resistance.^7,16 The reason for this remains a topic for future research. Recently, cyclosporine, infliximab and prednisolone have been used to treat IVIG-resistant patients.^20–24 Cyclosporine inhibits the dephosphorylation of nuclear factor of activated T cells and inhibits the release of cytokine molecules, especially IL-2, from activated T cells.^20–24 It should be determined whether recently developed therapies reduce the sIL-2R concentrations.

This study is associated with several limitations. The number of articles reviewed was limited, and the number of patients who were enrolled in the respective articles was small. The assays for measuring the serum sIL-2R concentrations could not be completely unified.¹⁶ Additionally, sIL-2R is reported to be present not only in the blood but also in the synovial/cerebrospinal fluid and urine.^25,26 Understanding the behaviour of sIL-2R in other specimens, in relation to serum sIL-2R, could yield information on the pathophysiology of KD and related complications, such as systemic vasculitis. Prospective long-term follow-up studies and interventional therapeutic studies to investigate the coronary outcomes, using the sIL-2R concentration, must be conducted. Further studies are thus required to draw any definitive conclusions.

Conclusions

The present study showed that the serum concentration of sIL-2R in patients with KD was high in comparison to controls. While it was only suggested that a high sIL-2R concentration might be seen in patients with CAAs, the sIL-2R concentration could be reduced after IVIG therapy. The serum sIL-2R may be a potent marker reflective of disease activity and therapeutic effects in patients with KD. Further studies should be performed for the use of sIL-2R as a marker of KD.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

This work was supported in part by Jichi Medical University.

Ethical approval

Not applicable.

Guarantor

KK.

Contributorship

HT participated in the design of the study, searched the literature, and wrote the draft of the manuscript. KK, TM, and OS participated in the design of the study and wrote the manuscript. TT and EK interpreted the findings and reviewed the manuscript. All authors approved the final version of the manuscript.

References

Kawasaki

Kosaka

Osawa

. A new infantile acute febrile mucocutaneous lymph node syndrome (MLNS) prevailing in Japan. Pediatrics 1973; 54: 271–276.

Makino

Nakamura

Yashiro

. Descriptive epidemiology of Kawasaki disease in Japan, 2011-2012: from the results of the 22nd nationwide survey. J Epidemiol 2015; 25: 239–245.

Singh

Vignesh

Burgner

. The epidemiology of Kawasaki disease: a global update. Arch Dis Child 2015; 100: 1084–1088.

Newburger

Takahashi

Burns

. Kawasaki disease. J Am Coll Cardiol 2016; 67: 1738–1749.

Matsubara

Yabuta

Furukawa

. Serum levels of tumor necrosis factor, interleukin 2 receptor, and interferon-gamma in Kawasaki disease involved coronary-artery lesions. Clin Immunol Immunopathol 1990; 56: 29–36.

Kim

. Serum interleukin-6 in Kawasaki disease. Yonsei Med J 1992; 33: 183–188.

Suzuki

Suenaga

Takeuchi

. Marker of T-cell activation is elevated in refractory Kawasaki disease. Pediatr Int 2010; 52: 785–789.

Yamamoto

Harigae

. Soluble interleukin 2 receptor – sIL2R. Diagn Treat 2009; 97: 244–245.

Kim

Imbert

Leonard

. Both integrated and differential regulation of components of the IL-2/IL-2 receptor system. Cytokine Growth Factor Rev 2006; 17: 349–366.

10.

Henter

Horne

Aricó

. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 2007; 48: 124–131.

11.

Kakisaka

Ohara

Katayama

. Human herpes virus type 6 can cause skin lesions at the BCG inoculation site similar to Kawasaki Disease. Tohoku J Exp Med 2012; 228: 351–353.

12.

Uchiyama

Kato

. The pathogenesis of Kawasaki disease and superantigens. Jpn J Infect Dis 1999; 52: 141–145.

13.

Matsubara

. Serum interleukin-2 receptor in patients with Kawasaki disease. Allergy 1989; 38: 49–56.

14.

Furumoto

Sakano

Tanabe

. Serum soluble CD8 antigen level is not elevated in mucocutaneous lymph node syndrome (Kawasaki disease) in spite of an increase in serum soluble interleukin 2 receptors. Eur J Pediatr 1990; 149: 448–449.

15.

Lin

Hwang

Chiang

. Cytokines predict coronary aneurysm formation in Kawasaki disease patients. Eur J Pediatr 1993; 152: 309–312.

16.

Peng

Chen

. Value of serum soluble interleukin-2R, interleukin-6 and C-reactive protein in the early diagnosis of Kawasaki disease. Chinese J Contem Pediatr 2006; 8: 208–210.

17.

Lang

Laxer

Rose

. Serum-soluble interleukin-2 receptor levels in Kawasaki disease. J Pediatr 1990; 116: 592–596.

18.

Barron

Joseph

Hilario

. Soluble interleukin-2 receptors in children with Kawasaki syndrome. Arthritis Rheum 1990; 33: 1371–1377.

19.

Ichiyama

Yoshitomi

Nishikawa

. NF-kappaB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Clin Immunol 2001; 99: 373–377.

20.

Minami

Shiraishi

Oka

. Continuous infusion of cyclosporin A in intravenous immunoglobulin resistant Kawasaki disease patients. Jichi Med Univ J 2011; 34: 109–115.

21.

Suzuki

Terai

Hamada

. Cyclosporin A treatment for Kawasaki disease refractory to initial and additional intravenous immunoglobulin. Pediatr Infect Dis J 2011; 30: 871–876.

22.

Tremoulet

Pancoast

Franco

. Calcineurin inhibitor treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr 2012; 161: 506–512.

23.

Burns

Song

Bujold

. Immune-monitoring in Kawasaki disease patients treated with infliximab and intravenous immunoglobulin. Clin Exp Immunol 2013; 174: 337–344.

24.

Kobayashi

Saji

Otani

. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet 2012; 379: 1613–1620.

25.

Alenius

Eriksson

Rantapää Dahlqvist

. Interleukin-6 and soluble interleukin-2 receptor alpha-markers of inflammation in patients with psoriatic arthritis? Clin Exp Rheumatol 2009; 27: 120–123.

26.

Gilad

Lampl

Eshel

. Cerebrospinal fluid soluble interleukin-2 receptor in cerebral lupus. Br J Rheumatol 1997; 36: 190–193.